This Visio flowchart shows how forms come due when the infusion is Post-Transplant Cellular Therapy (does not include DLIs).
Last modified:
Sep 23, 2022
- Welcome
- Public Health Authority and Protected Health Information
- Protocols and Consents
- Fee Schedule
- Access to CIBMTR Systems
- Center Participation
- Continuous Process Improvement Program (CPI)
- Center Compliance
- Regulatory Documentation Standards
- Form Completion Standards
- CPI Resources
- Consecutive Transplant Audit (CTA)
- Step 1: Report Infusions in FormsNet3℠
- Step 2: US Centers – Submit CTA List to CIBMTR
- Step 2: International Centers – Submit CTA List to CIBMTR
- Step 3: CTA Discrepancy Process
- Downloading CTA Files
- External Deliverables
- FormsNet3℠ Process and Tool Instructions
- Data Collection and Quality
- FormsNet3℠
- AGNIS
- How Forms Come Due
- Cellular Therapy
- Correcting Historical Data
- Primary Disease and Disease Forms Due
- Acute myelogenous leukemia (AML or ANLL)
- Acute lymphoblastic leukemia (ALL)
- Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms
- Chronic myelogenous leukemia (CML)
- Myelodysplastic (MDS)
- Myeloproliferative Neoplasms (MPN)
- Other Leukemia
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- NHL-Waldenstrom
- Multiple Myeloma/Plasma Cell Disorder (PCD)
- Solid Tumors
- Aplastic Anemia
- Inherited Bone Marrow Failure Syndromes
- Hemoglobinopathies
- Disorders of the immune system
- Inherited abnormalities of platelets
- Inherited disorders of metabolism
- Histiocytic disorders
- Autoimmune diseases
- Quarterly Form Revision Schedule
- Monthly Maintenance Items for FormsNet3
- NMDP Forms
- Corporate Studies and Registries
- Online Training
- Acronyms
- Quick Links
- Contact Us